3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Primary Malignant Peripheral Nerve Sheath Tumors
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myelomonocytic, Chronic
1
GATA2 Deficiency
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cyclophosphamide
3
sodium-iodide symporter
1
ruxolitinib
1
fludarabine phosphate
1
fludarabine
1
cemiplimab
1
X-Rays
1
Whole-Body Irradiation
1
Vorinostat
1
Tacrolimus
1
Specimen Handling
1
Sirolimus
1
Photons
1
Peripheral Blood Stem Cell Transplantation
1
Particle Accelerators
1
Nivolumab
1
Mycophenolic Acid
1
Methotrexate
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Immunoglobulin G
1
Etoposide
1
Disulfides
1
Cyclosporine
1
CTLA-4 Antigen
1
Busulfan
1
Biopsy
1
A-dmDT390-bisFv(UCHT1) protein
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Cutaneous
×
Vorinostat
×
30 days
×
Clear all
NCT02943642
2026-05-18
Resimmune®
Virogen Biotechnology Inc.
Phase 2
Withdrawn